On April 26th 2023, the European Commission released a proposal for revision of the Pharmaceutical legislation, which includes provisions on medicines for paediatric and rare diseases.
Over the summer, CCI-E‘s and SIOPE‘s policy teams carried out an in-depth analysis of the proposal and identified six key priority areas which require careful consideration during the negotiation of the revised EU Pharmaceutical legislation among EU policy-makers.
Based on this analysis, CCI-E and SIOPE drafted a position paper detailing points which should be upheld, as well as areas with specific suggestions for amendments which can further strengthen the reform and ultimately, improve the well-being of children and young cancer patients with unmet medical needs and restore them to their full health.
This joint position paper was shared with all the MEPs and other stakeholders with whom the policy team has met since mid-August and used as a support to advocate our concerns.
We invite you to read it.
Should you have any questions, do not hesitate to contact Teresa Pais (firstname.lastname@example.org) or Marine Gouders (email@example.com).